BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Solar storms can trigger auroras on Earth. This star’s explosion could destroy a planet’s atmosphere - 2'Here we go again': Businesses grapple with fuel costs
- 3The Response Uncovered: Disentangling the Secrets of the Universe
- 4'Something Very Bad Is Going to Happen' is the Duffer Brothers' first project since 'Stranger Things.' It's also 'wildly insane.'
- 5Ever Wonder What An EV Motorcycle Water Crossing Would Be Like? Here You Go
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
- Must-See Public Parks from Around the Globe
- Best Augmented Simulation Ride: Which One Feels Generally Genuine?
- The most effective method to Examine a Cellular breakdown in the lungs Finding with Family
- Anger as German family business group opens talks with far-right AfD
- Inside the alleged Russian operation to trigger anti-government protests in Angola
- Iran fires one of largest barrages in weeks ahead of Passover
- Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
